60 Degrees Pharmaceuticals, Inc. SXTP
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is an infectious disease drug developer. Its lead program, Arakoda (tafenoquine), is in Phase 2 for Malaria prophylaxis/prevention. Its next catalyst on record is tafenoquine: Company expects to unblind its randomized, placebo-controlled study of tafenoquine in patients hospitalized for babesiosis in January 2027. (January 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tafenoquine — Company expects to unblind its randomized, placebo-controlled study of tafenoquine in patients hospitalized for babesiosis in January 2027. (January 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Arakoda (tafenoquine) | Malaria preventative treatment | small molecule | Approved |
| Tafenoquine | Babesiosis | small molecule | Phase 2 |
Recent results and decisions
- Oct 27, 2026positive All five completed patients in expanded access study reported clinical improvement and tested negative for Babesia on conventional PCR tests.
All five patients reported being much improved or very much improved on study-completion forms, and each had negative conventional polymerase chain reaction (PCR) test results for Babesia documented during treatment or subsequent follow-up.
Filing - Oct 23, 2026mixed Interim chronic babesiosis study screening has not produced species-specific B. microti signal in 2 of 9 subjects screened.
2/9 Genus-level molecular screening signal Early chronic-study screening has not produced a species-specific B. microti signal.
Filing - Oct 23, 2026positive First three expanded-access patients were NAT-negative after tafenoquine treatment, with cases 4-5 approaching disclosure.
The first three patients were NAT-negative after treatment; cases 4–5 are approaching disclosure.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.